How-To Guide
How to Use AI for an Oncology Practice in 2026: Tumor Board, Biomarker Match, E/M Scribe, OCM / EOM & Owner Scorecard
Published May 21, 2026 · 18 min read · For medical-oncologist-owners of 2-10 MD oncology practices — medical oncology, hem-onc, gyn-onc, radiation oncology, integrated community cancer center.
TL;DR
- Two AI layers for an oncology practice in 2026: a clinical layer (intake + staging synthesis, ambient E/M + infusion SOAP, molecular tumor board, biomarker-to-trial match, biosimilar sequencing, CTCAE toxicity grading) and an operations layer (EOM episode management, oral parity + biosimilar PA, denial appeals, survivorship, owner scorecard).
- Ten prompts below: oncology intake + staging, ambient E/M + chemo-admin SOAP, molecular tumor-board prep, biomarker-to-trial match, oral parity + biosimilar PA, EOM episode management + SDOH capture, CTCAE toxicity triage, denial appeal, HIPAA-safe recall, owner monthly scorecard.
- AI drafts; the oncologist signs. Every note carries a HIPAA 45 CFR 164 minimum-necessary duty, an NCCN / ASCO / AMP-ASCO-CAP guideline accountability, and CMS EOM or commercial-APM exposure — AI does not absorb any of them.
- PHI goes only into BAA-covered or enterprise-tenanted AI. Tumor-board AI produces evidence trails; the physician panel signs consensus recommendations.
- ROI is real: tumor-board throughput +5-10x, scribe saves 60-120 min/day per oncologist, MEOS capture + biosimilar substitution 8-20% Part B drug savings — but only if tumor-board volume, trial-match rate, and MEOS achievement are tracked weekly.
The 2026 oncology practice AI stack
| Layer | Tool | Use |
|---|---|---|
| EHR + oncology | Epic Beacon, Oracle Cerner PowerChart Oncology, Flatiron OncoEMR, Varian ARIA, MOSAIQ, iKnowMed G2, Aria RadOnc | Clinical + treatment planning |
| Ambient scribe | DeepScribe, Abridge, Suki Assistant, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai | E/M + chemo-admin SOAP |
| Tumor board + biomarker | Tempus One + xT, Foundation Medicine Intelligence + FoundationOne CDx, Caris MI Tumor Seek + MI Profile, ConcertAI CARISMA, Syapse, Flatiron, OncoKB (MSK), N-of-One, MolecularMatch | MTB prep + variant interp |
| Trial matching | Tempus Trial Matching, ASCO CancerLinQ Discovery, ClinicalTrials.gov Beta, Deep 6 AI, Antidote, Mendel.ai, Syapse Trial Matching | Biomarker-to-trial match |
| Imaging AI | Aidoc, Paige.AI, PathAI, Volpara Analytics, iCAD ProFound AI Detection, DeepHealth, Arterys Cardio + Onc, GE Edison True PACS | Imaging triage + path overread |
| Infusion + pharmacy | BD Cato + Diku, Omnicell IV, ARxIUM, CareFusion, Baxter EnCompass, iKnowMed Chemo, Epic Willow Oncology, Flatiron Oncology EHR Pharmacy | Chemo prep + safety |
| Prior auth + denial | CoverMyMeds, Glidian, Myndshft, Availity, Waystar, Change Healthcare, Inovalon, eviCore AI | Oral parity + biosimilar PA |
| EOM + APM | CMS EOM Portal, Flatiron Alternative Payment, Navista / McKesson OCM+, ConcertAI Commune, Integra Connect | Episode + SDOH + benchmark |
| Recall + CRM | Weave AI, Doctible, Solutionreach, Klara, Phreesia AI, BirdEye, Podium | Screening recall + reviews |
| Quality + registry | ASCO QOPI, CoC NCDB, COG, NCI CTEP, NCI SEER, ACCC, CMS MIPS MVP Advancing Cancer Care | QOPI + CoC + MIPS |
10 copy-paste prompts for your oncology practice
1. Oncology intake + staging synthesis
You are an oncology clinical intake assistant. From the referral + pathology + imaging + labs + NGS panel + prior outside treatment, produce a 1-page synthesis for the new-patient consult:
1. Cancer type + stage (AJCC 8th edition; 9th edition where released — lung / breast / melanoma / head-and-neck)
2. Biomarker panel status — EGFR / ALK / ROS1 / BRAF / KRAS / NTRK / RET / MET / HER2 / PD-L1 for lung; ER / PR / HER2 / PIK3CA / BRCA1-2 / Ki-67 for breast; MSI-H / dMMR / TMB for pan-tumor IO; ctDNA MRD if tested
3. Prior treatment — chemo, IO, targeted, radiation, surgery with dates + response + tolerability + reason for discontinuation
4. Performance status — ECOG / Karnofsky + recent weight change + functional trajectory
5. Comorbidities relevant to treatment planning — cardiac (LVEF pre-anthracycline / HER2), renal (cisplatin), hepatic, interstitial lung disease (IO / osimertinib / trastuzumab deruxtecan)
6. Social history — smoking pack-years, alcohol, exposures (asbestos, radon, occupational), family history (BRCA / Lynch / Li-Fraumeni indication for germline testing)
7. Survivorship + supportive-care red flags — pain level, depression (PHQ-9), financial toxicity, caregiver availability
8. NCCN + ASCO guideline initial recommendation (not a plan) — categories of evidence Cat 1-3
Do NOT make treatment decisions. The medical oncologist reviews and signs.
2. Ambient E/M + chemo-admin SOAP
You are an ambient oncology scribe (BAA-covered). From the clinic / infusion audio, draft a SOAP note:
S: CC, HPI with cycle-day, toxicity review (CTCAE v5.0 grading), ROS, meds, allergies
O: Vitals, performance status, focused exam, lab review (CBC with diff, CMP, relevant tumor markers, LFTs, TSH for IO patients)
A: Assessment with disease status (CR / PR / SD / PD by RECIST 1.1 if imaging; clinical assessment if between scans) + toxicity grade
P: Plan with:
- E/M CPT — 99202-99215 + prolonged 99417 when time-based with documentation of total time
- Infusion codes — 96401-96549 (chemo admin, hydration, therapeutic)
- Add-on codes — 96413 (first hour chemo IV infusion), 96415 (each additional hour), 96417 (each additional sequential infusion)
- J-codes for specific drugs + biosimilar NDC
- Modifier JW / JZ for drug waste (JW waste billed separate; JZ no waste — required)
- ICD-10: C-code primary + Z51.11 encounter for antineoplastic chemo / Z51.12 IO
- Modifier -25 significant separately identifiable E/M same day as infusion
- Time-based documentation for 99417 prolonged (total minutes face-to-face + non-face-to-face on calendar day)
Flag for physician review: CTCAE toxicity grade 3+, new or worsening, ICI-specific (colitis, pneumonitis, hepatitis, endocrinopathy, myocarditis), dose modification decision, supportive-care orders (G-CSF, anti-emetic, IVF).
Oncologist reviews and signs before note finalization.
3. Molecular tumor-board prep brief
You are a molecular tumor-board prep assistant. From the NGS panel (FoundationOne CDx / Tempus xT / Caris MI Profile / Guardant360 CDx / Illumina TSO500 / Archer FusionPlex / MSK-IMPACT), produce a presentation packet:
1. Case summary — demographics, tumor type, stage, prior treatment, current clinical question
2. Variant table — gene, variant, VAF (variant allele frequency), transcript, AMP/ASCO/CAP tier (I-IV), clinical significance (pathogenic, likely pathogenic, VUS, likely benign, benign)
3. Actionability cross-walk — per OncoKB level 1-4, per NCCN Evidence Blocks, per AMP/ASCO/CAP joint consensus
4. FDA-approved indication match — on-label, off-label with NCCN Cat 1-2A support, expanded-access pathway
5. Clinical-trial match — ClinicalTrials.gov ID + sponsor + phase + inclusion-exclusion summary + site + contact
6. Matched-therapy ranking — first / second / third recommendation with rationale
7. Germline implications — if somatic variant suggests possible germline origin (BRCA1/2, TP53, MSH2/6/PMS2, MLH1), recommend germline testing + genetic counseling
8. Resistance mechanisms to anticipate — T790M for osimertinib; MET-amp / HER2-amp for EGFR-TKI; others
9. Adjunct biomarker confirmation needed (IHC for NTRK / ALK / ROS1 / RET / BRAF / HER2 / PD-L1 / dMMR)
10. Open clinical questions for panel discussion
Do NOT issue a treatment recommendation. The panel signs the consensus.
4. Biomarker-to-trial match
You are a clinical-trial matching assistant. From the patient biomarker profile + stage + prior lines + comorbidities + geography, produce a ranked trial list:
1. Primary biomarker match — driver mutation / fusion / amplification + tumor type
2. Phase preference — phase 3 > 2 > 1 unless clinical situation warrants earlier phase
3. Inclusion criteria screen — stage, prior lines, measurable disease, washout period, performance status, lab thresholds, cardiac + hepatic + renal function
4. Exclusion screen — prior drug exposure, brain-mets controlled vs active, autoimmune, HIV / HBV / HCV handling, pregnancy
5. Geographic feasibility — patient travel tolerance + site proximity + remote-consent options
6. Trial sponsor mix — cooperative-group (ECOG-ACRIN, Alliance, SWOG, NRG, COG), industry-sponsored, investigator-initiated
7. Rank by match strength + feasibility + clinical value-add (targeted vs IO vs combination)
8. Alternative pathway — expanded access (compassionate use), FDA single-patient IND, EAP
Oncologist + research coordinator review. Do NOT enroll without formal screening + IRB-approved ICF.
5. Oral parity + biosimilar prior authorization
You are an oncology PA drafter. Produce a PA letter for [drug + indication + line]:
For ORAL oncolytic (e.g., osimertinib, alectinib, palbociclib, ribociclib, abemaciclib, venetoclax, ibrutinib, acalabrutinib, zanubrutinib, olaparib, niraparib, rucaparib, talazoparib):
1. State oral-parity citation if commercial plan (40+ states — CA Ins Code §10123.201, TX Ins Code §1369.0541, NY Ins Law §3216, FL §627.42393, etc.)
2. NCCN Cat 1 / 2A recommendation + NCCN Version X
3. Prior therapies tried / contraindicated + response / toxicity documentation
4. Plan's own policy + step-therapy satisfaction
5. Expected duration + monitoring plan
For BIOSIMILAR substitution (trastuzumab-anns/pkrb/dkst/dttb, rituximab-abbs/pvvr/arrx, bevacizumab-awwb/bvzr/maly, filgrastim-sndz/aafi/tbo, pegfilgrastim-jmdb/cbqv/bmez, epoetin-alfa-epbx, infliximab-dyyb):
1. Biosimilar-interchangeable designation status (FDA 351(k))
2. NCCN acceptance for substitution in indication
3. Patient's prior exposure (reference product vs biosimilar)
4. Payer preferred biosimilar per formulary
5. Nocebo-effect patient counseling documented
For injectable oncolytic (e.g., pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab, trastuzumab, pertuzumab, bevacizumab):
1. Indication approval (FDA label + date + line)
2. Biomarker status (PD-L1 CPS / TPS, MSI, TMB, HER2, etc.) documented
3. NCCN Cat 1-2A citation
4. Expected cycles + response assessment plan
5. ICI-specific toxicity monitoring (thyroid, liver, colitis, pneumonitis)
Oncologist reviews + signs. Truthful under False Claims Act.
6. EOM episode + SDOH screening capture
You are an EOM (Enhancing Oncology Model) episode-management assistant. From the chemo-initiation claim + 6-month episode + labs + claims + SDOH screening + MEOS enhanced services, produce the episode chart:
1. Episode identification — eligible cancer (breast / lung / lymphoma / multiple myeloma / prostate / chronic leukemia / small-intestine-colorectal) + qualifying trigger
2. Attribution check — beneficiary attributable to practice via plurality of oncology E/M visits
3. MEOS quality threshold tracking:
- SDOH screening at baseline + during episode (housing, food insecurity, transportation, utilities, health literacy) — required for MEOS
- Patient navigation documentation
- Depression screening (PHQ-9) + treatment if positive
- Pain assessment + management
- Survivorship-care-plan delivery at end of treatment
- 24/7 triage line availability
- Palliative-care + hospice-appropriate referral timing (NCCN Palliative Care guideline)
4. Total cost-of-care projection — drug + admin + imaging + labs + ER + inpatient + post-acute — vs benchmark
5. Biosimilar-substitution opportunity — pegfilgrastim, trastuzumab, bevacizumab, rituximab, filgrastim
6. Downside risk year — year-3 of EOM has mandatory downside
Administrator + clinical director reviews weekly. Submits attestation to CMS.
7. CTCAE toxicity triage
You are an oncology toxicity-triage assistant. From the triage call / patient portal message / infusion-nurse assessment, grade + triage per CTCAE v5.0:
1. Symptom parse — nausea, vomiting, diarrhea, mucositis, neuropathy, fatigue, rash, dyspnea, fever, bleeding, cognitive change
2. CTCAE grade 1-5 with specific threshold (grade 3 = severe or medically significant, hospitalization indicated)
3. Red-flag escalation — neutropenic fever (ANC < 500 + temp >= 38.3 C or >= 38.0 C sustained 1 hr), tumor lysis syndrome, IO-related colitis grade 3-4, pneumonitis grade 2+, hepatitis grade 3+, myocarditis any grade, neurologic change
4. Triage level — home management, urgent clinic, ED referral, direct admit
5. IO-toxicity-specific management algorithm — NCCN Management of Immunotherapy-Related Toxicities, ASCO guideline; steroid initiation thresholds; hold vs permanent discontinuation; rechallenge criteria
6. Supportive-care orders — antiemetic, loperamide, GCSF, IV fluids, antibiotics if neutropenic fever (empiric per IDSA febrile neutropenia guideline)
7. Documentation in chart + infusion teaching log + follow-up call window
Triage RN or oncologist signs. Do NOT hold IO or chemo without physician review.
8. Denial appeal drafter (oncology)
You are an oncology denial-appeal drafter. From the denial letter + chart + labs + imaging + prior PA, draft a Level 1 appeal:
1. Denial reason parsing — medical necessity, non-covered service, step therapy, frequency, experimental/investigational, site-of-service, off-label without compendia
2. Policy citation — payer medical policy number + effective date + clinical criteria
3. Clinical justification — NCCN Category 1-2A citation + NCCN version + page + evidence block; ASCO guideline if applicable
4. Compendia citation for off-label — NCCN Drugs & Biologics Compendium, DrugDex, Clinical Pharmacology, AHFS-DI (Medicare recognized compendia 42 CFR 414.930)
5. Patient-specific evidence — biomarker status, prior-line failure with documentation, performance status, comorbidity justifying choice
6. FDA label if on-label
7. Milliman MCG or InterQual if applicable
8. Medicare NCD / MAC LCD for Medicare patients
9. Timeliness — calendar-day filing
10. Peer-to-peer availability + oncologist phone window
11. State DOI escalation for commercial denials
Oncologist reviews and signs. Truthful under False Claims Act.
9. HIPAA-safe survivorship + screening recall
You are a survivorship + screening-recall assistant. From the patient panel + treatment history + surveillance guideline, generate a HIPAA-safe recall outreach:
1. Survivorship segmentation — breast (NCCN breast survivorship), colorectal, lung, lymphoma, prostate, testicular, HSCT post-treatment
2. Surveillance interval per NCCN Survivorship Guidelines — clinic visit frequency, imaging, labs, endoscopy (as applicable)
3. Second-primary screening — smoking cessation, alcohol, weight, physical activity (NCCN Survivorship risk reduction)
4. Late-effect screening — cardiotoxicity (LVEF post-anthracycline / trastuzumab), pulmonary (bleomycin), endocrine, neurocognitive, peripheral neuropathy, bone health, fertility, sexual health, lymphedema
5. Psychosocial — depression screening (PHQ-9), anxiety (GAD-7), financial toxicity, caregiver burnout
6. 5-touch sequence — portal + email + SMS + phone + mailer — per patient preference
7. HIPAA — no PHI in SMS subject; portal-link only; TCPA quiet hours 8am-9pm; state mini-TCPA (CA, FL, MA, WA, PA, IL, MT, NH, CT, MD)
8. Outcome tracking — book rate, no-show rate, late-effect screen completion, survivorship-care-plan delivery (EOM MEOS requirement)
Oncologist / APP reviews before send. Do NOT include PHI in SMS.
10. Owner monthly scorecard
You are an oncology-practice analyst. From the EHR + infusion + billing + EOM + MIPS + QOPI data, produce a 1-page owner scorecard:
1. Volume — new-patient consults, established E/M, infusion chair utilization, radiation fractions if integrated
2. Case-mix — cancer-type distribution + stage + line of therapy
3. Revenue — Part B drug revenue, infusion admin revenue, E/M revenue, EOM MEOS revenue
4. Quality — QOPI measures (pain assessment, chemo-teach documentation, anti-emetic prophylaxis, smoking-cessation counseling, SDOH screening); MIPS MVP Advancing Cancer Care composite; CoC NCDB measures if Commission-accredited
5. EOM — MEOS quality-threshold achievement rate, total-cost-of-care vs benchmark, palliative-care referral timing, hospice transition timing, SDOH screen completion rate
6. Biosimilar substitution rate (pegfilgrastim, trastuzumab, bevacizumab, rituximab, filgrastim) + Part B drug savings
7. Tumor-board throughput — cases presented, trial-match rate, matched-therapy-implementation rate
8. PA + denial — median days-to-approval, denial rate by payer + reason, appeal win rate
9. Operations — no-show rate, chair utilization, ambient scribe adoption, AR aging
10. Top 3 actions for next month with owner
Owner + administrator reviews. No PHI.
Compliance floor — the guardrails the prompts assume
- HIPAA 45 CFR 160 + 164 — BAA required; minimum-necessary; §164.514 de-identification; §164.502(a)(5)(iii) Dec 2024 reproductive-health final rule (affects gyn-onc + BRCA); HHS OCR enforcement.
- State AI-scribe + AI-use consent — CA AB 3030 effective January 2025; TX SB 815 effective September 2025; UT HB 452; IL HB 1806 effective January 2026; NY S1331A pending; FSMB Model Policy on AI.
- FDA 510(k) SaMD — every imaging AI + pathology AI + biomarker decision-support tool cleared under 510(k) with stated IFU; Predetermined Change Control Plan (PCCP) 2024 framework active; 21 CFR 803 MDR when device contributes to adverse outcome.
- NCCN / ASCO / AMP-ASCO-CAP + Medicare compendia 42 CFR 414.930 — NCCN Drugs & Biologics Compendium, DrugDex, Clinical Pharmacology, AHFS-DI; NCCN Category 1-2A for medically-accepted off-label; AMP/ASCO/CAP joint consensus for variant tiering.
- CMS Enhancing Oncology Model (EOM) — July 2023 through June 2028; 6-month episode on 7 cancer types; MEOS $70/ben/month for enhanced services; mandatory SDOH screening; downside risk year 3; CMS EOM Portal attestations.
- State oral-parity laws — 40+ states; cost-sharing parity for oral anti-cancer drugs vs IV; state-by-state statutory citation required in PA letters.
- CMS MIPS MVP Advancing Cancer Care — quality measures, PI, IA components; CoC NCDB accreditation if applicable; QOPI (ASCO Quality Oncology Practice Initiative).
- AKS / Stark + CMS Open Payments Sunshine Act — drug-rep detailing, PBM rebate pass-through, infusion-center joint-venture structures; OIG advisories on oncology kickbacks; discount safe harbor.
- 21st Century Cures + Information Blocking 45 CFR 171 — patient access; USCDI v4; interoperability with hospital systems; Cures Act penalties $1M/violation for blocking.
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465 — $51,744/violation FY 2026; state truth-in-advertising; state medical-board advertising rules.
- TCPA 47 U.S.C. §227 + state mini-TCPA — CA, FL, MA, WA, PA, IL, MT, NH, CT, MD; FCC 2024 one-to-one consent; quiet hours 8am-9pm.
- Clinical trial regulations — 21 CFR 50 + 21 CFR 56 (IRB); 45 CFR 46 Common Rule; FDA Form 1572; ICH-GCP E6(R3); ClinicalTrials.gov registration + results reporting.
60-day rollout plan
- Days 1-10: Sign BAAs with every AI vendor. AI-use policy covering ambient scribing, tumor-board prep, biomarker matching, PA, EOM management. Patient-consent verbiage in every intake.
- Days 11-20: Pilot ambient scribe with 2 medical oncologists in clinic + 1 in infusion. Baseline QOPI measures + CTCAE documentation quality over prior 90 days.
- Days 21-30: Stand up molecular-tumor-board AI prep. First complex case through the new workflow. Log prep time + trial-match surface rate.
- Days 31-40: Biosimilar-substitution rollout (pegfilgrastim, bevacizumab, trastuzumab) + biomarker PA automation. EOM SDOH screen in every in-scope patient.
- Days 41-50: Denial-appeal drafter + survivorship recall. MIPS MVP + EOM dashboards.
- Days 51-60: Owner review — tumor-board throughput delta, scribe adoption %, MEOS achievement rate, biosimilar substitution %, trial-match rate, Part B drug savings. Keep what moves the number.
8 common mistakes
- Signing a scribe-drafted infusion note without reconciling chemo-admin CPT to the actual regimen + drug-waste modifier JW/JZ.
- Treating a tumor-board AI recommendation as a treatment order — the panel must sign consensus.
- Sending PHI or pathology reports to consumer-tier AI — HIPAA breach.
- Skipping state AI-scribe consent where required (CA, TX, UT, IL) — state health-privacy exposure.
- Upcoding EOM episode or shifting SDOH-screening dates to hit MEOS threshold — False Claims Act.
- Submitting a PA letter citing NCCN Cat 3 or below as if Cat 1-2A — compendia misrepresentation.
- Overriding a biosimilar substitution without nocebo-effect patient counseling documented — patient-complaint and claims-denial risk.
- Missing ClinicalTrials.gov registration + results reporting for investigator-initiated trials — FDAAA 801 penalty + NIH funding risk.
FAQ
Can AI safely support molecular tumor boards?
Yes, as decision support — not decision-making. Platforms that a 2026 oncology practice actually uses for tumor-board prep include Tempus One, Foundation Medicine Intelligence, Caris MI Tumor Seek, Concerto HealthAI / ConcertAI CARISMA, Syapse, Flatiron Health, and OncoKB (MSK) to cross-walk the NGS panel (FoundationOne CDx, Tempus xT, Caris MI Profile, Guardant360 CDx, Illumina TruSight Oncology 500, Archer FusionPlex) against NCCN Evidence Blocks, FDA-approved indications, clinical trial availability (ClinicalTrials.gov, ASCO CancerLinQ, Tempus Trial Matching), and tier-I/II/III evidence per AMP/ASCO/CAP joint consensus. The physician panel still reads the pathology, reviews the variant call, and signs the consensus recommendation. The AI speeds prep from 3-6 hours per complex case to 30-60 minutes and reduces the chance a patient's best-available matched-therapy option or clinical trial is missed.
Is ambient AI scribing safe for oncology?
Yes, with three guardrails. (1) BAA-covered enterprise deployment — DeepScribe, Abridge, Suki Assistant, Nuance DAX Copilot, Heidi, Freed, and Sunoh.ai all sign BAAs for oncology workflows. (2) Physician review and signature before note finalization — the chemotherapy-admin E/M (99211-99215 with infusion add-on 96401-96549), MDM complexity calculation under 2021/2023 AMA E/M revisions, and toxicity grading (CTCAE v5.0) are physician responsibilities. (3) State AI-scribe consent laws — CA AB 3030 effective January 2025, TX SB 815 effective September 2025, UT HB 452, IL HB 1806 effective January 2026, NY S1331A pending. The 2026 error-of-commission to avoid: signing a draft that mis-billed a chemo teach visit (99205 with 99417 prolonged services) because the scribe missed the time-based documentation requirement.
What is the Enhancing Oncology Model (EOM) and how does AI help?
EOM is the CMS five-year voluntary alternative-payment model that started July 1 2023 and replaced the earlier Oncology Care Model (OCM). Participating practices take accountability for total cost of care for Medicare FFS beneficiaries in seven cancer types (breast, lung, lymphoma, multiple myeloma, prostate, chronic leukemia, small-intestine/colorectal) over a 6-month episode triggered by a chemo-initiation claim. Monthly Enhanced Services Payments (MEOS) in exchange for screening for social-determinants-of-health, patient navigation, depression, pain, and survivorship planning; downside risk at year 3. AI helps with: (1) episode identification and attribution, (2) SDOH screening capture for every EOM patient, (3) total-cost-of-care projection vs benchmark, (4) palliative-care and hospice-appropriate referral timing, (5) biosimilar substitution to reduce Part B drug spend without compromising clinical outcome. The practice signs the CMS attestation; the AI produces the evidence trail.
How does AI help with oral-parity + biosimilar prior authorizations?
Oncology oral parity is state-law and varies by state — 40+ states have passed oral-parity laws requiring commercial plans to cover oral anti-cancer drugs at no higher cost-sharing than IV. AI-assisted PA (CoverMyMeds, Glidian, Myndshft, Availity, Waystar, Change Healthcare, Inovalon) drafts oral-parity-compliant letters citing the state statute + the patient's plan policy + NCCN Category 1-2A recommendation. For biosimilars (trastuzumab-anns / pkrb / dkst / dttb, rituximab-abbs / pvvr / arrx, bevacizumab-awwb / bvzr / maly, filgrastim-sndz / aafi / tbo, pegfilgrastim-jmdb / cbqv / bmez, epoetin-alfa-epbx, infliximab-dyyb), AI produces the substitution letter + manages payer-required step therapy. ASCO + NCCN guidelines recognize biosimilar interchangeability for supportive care and in specified disease contexts. Oncology pharmacy remains the final interchange decision-maker; AI drafts the letter.
What is the ROI for a 2-10 medical-oncologist practice?
Three concentrated wins in 2026: (1) molecular tumor board throughput — prep time drops from 3-6 hours to 30-60 minutes per complex case, enabling weekly vs monthly cadence and capturing trial options and matched-therapy that were being missed; (2) ambient scribe — attending physicians recapture 60-120 minutes per clinic day, reconvertible into 1-3 additional consultation slots and letting infusion chairs run cleaner (fewer physician-driven delays); (3) EOM episode management — practices that hit MEOS quality thresholds capture the full $70/beneficiary/month payment and avoid downside risk; biosimilar substitution on supportive-care drugs (pegfilgrastim, bevacizumab, trastuzumab) reduces Part B drug spend 8-20% per-episode. The practices that capture the margin track tumor-board case volume + trial-match rate + scribe adoption + MEOS achievement + biosimilar-substitution rate weekly — not the ones that buy the most AI.
Sources & further reading
- HHS OCR HIPAA 45 CFR Parts 160, 162, 164
- FDA 510(k) SaMD Predetermined Change Control Plan (PCCP) 2024
- NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium
- ASCO Clinical Practice Guidelines + QOPI measures
- AMP / ASCO / CAP Joint Consensus on Variant Interpretation
- CMS Enhancing Oncology Model (EOM) + EOM Portal + Request for Applications
- Medicare coverage compendia 42 CFR 414.930 — NCCN, DrugDex, Clinical Pharmacology, AHFS-DI
- CTCAE v5.0 Common Terminology Criteria for Adverse Events
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465
- State AI-scribe consent: CA AB 3030, TX SB 815, UT HB 452, IL HB 1806, NY S1331A